These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34556625)

  • 1. [Prescription of acetylcholinesterase inhibitors and memantine in the Canary Islands, comparison with the Spanish population.].
    Rodríguez-Espinosa N; González-Colaço Harmand M; Miranda Saavedra F; Galván González MÁ; Plasencia Núñez M; Aldea Perona AM; Boada C
    Rev Esp Salud Publica; 2021 Sep; 95():. PubMed ID: 34556625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of antipsychotics in patients with dementia in Spain: Comparison with prescription of acetylcholinesterase inhibitors and memantine and analysis of associations].
    Rodríguez Espinosa N; Gonzalez-Colaço Harmand M; Moro Miguel MA
    Rev Esp Geriatr Gerontol; 2024; 59(2):101446. PubMed ID: 38029634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated prevalence of dementia based on analysis of drug databases in the Region of Madrid (Spain).
    de Hoyos-Alonso MC; Bonis J; Tapias-Merino E; Castell MV; Otero A
    Neurologia; 2016; 31(1):1-8. PubMed ID: 25444413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012.
    de Hoyos-Alonso MC; Tapias-Merino E; Meseguer Barros CM; Sánchez-Martínez M; Otero A
    Neurologia; 2015 Sep; 30(7):416-24. PubMed ID: 24704249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quality of registration of dementia diagnosis in primary care: The situation in Spain in 2002-2011].
    de Hoyos-Alonso Mdel C; Bonis J; Bryant V; Castell Alcalá MV; Otero Puime Á
    Aten Primaria; 2016 Jan; 48(1):33-41. PubMed ID: 26026620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in the prescription of cholinesterase inhibitors and memantine.
    Villar-Fernández I; Bjerrum L; Feja C; Rabanaque MJ
    Dement Geriatr Cogn Disord; 2009; 28(4):373-9. PubMed ID: 19887800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.
    Calvó-Perxas L; Turró-Garriga O; Vilalta-Franch J; Lozano-Gallego M; de Eugenio R; Márquez F; Carmona O; Gich J; Manzano A; Viñas M; Roig AM; Garre-Olmo J;
    Drugs Aging; 2017 Apr; 34(4):303-310. PubMed ID: 28258538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrocardiographic monitoring for new prescriptions of quetiapine co-prescribed with acetylcholinesterase inhibitors or memantine from 2005 to 2009. A population study on community-dwelling older people in Italy.
    Bilotta C; Franchi C; Nobili A; Nicolini P; Djade CD; Tettamanti M; Pasina L; Fortino I; Bortolotti A; Merlino L; Vergani C
    Eur J Clin Pharmacol; 2014 Dec; 70(12):1487-94. PubMed ID: 25234794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink.
    Walker VM; Davies NM; Kehoe PG; Martin RM
    Alzheimers Res Ther; 2018 May; 10(1):51. PubMed ID: 29843807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of Medicare prescription drug coverage on the use of antidementia drugs.
    Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM
    BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study.
    Vaci N; Koychev I; Kim CH; Kormilitzin A; Liu Q; Lucas C; Dehghan A; Nenadic G; Nevado-Holgado A
    Br J Psychiatry; 2021 May; 218(5):261-267. PubMed ID: 32713359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany.
    Hoffmann F; van den Bussche H; Glaeske G; Kaduszkiewicz H
    Int Clin Psychopharmacol; 2010 Jan; 25(1):29-36. PubMed ID: 19934763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
    Raina P; Santaguida P; Ismaila A; Patterson C; Cowan D; Levine M; Booker L; Oremus M
    Ann Intern Med; 2008 Mar; 148(5):379-97. PubMed ID: 18316756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].
    Portela Romero M; Pombo Romero J; Bugarín González R; Tasende Souto M; Represa Veiga S
    Rev Esp Salud Publica; 2005; 79(6):665-72. PubMed ID: 16457058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disproportionately high incidence of diabetes-related end-stage renal disease in the Canary Islands. An analysis based on estimated population at risk.
    Lorenzo V; Boronat M; Saavedra P; Rufino M; Maceira B; Novoa FJ; Torres A
    Nephrol Dial Transplant; 2010 Jul; 25(7):2283-8. PubMed ID: 20064954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
    Rojas G; Demey I; Arizaga RL
    Medicina (B Aires); 2013; 73(3):213-23. PubMed ID: 23732196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study.
    Beauchet O; Launay CP; Allali G; Watfa G; Gallouj K; Herrmann FR; Annweiler C
    BMC Neurol; 2013 Nov; 13():184. PubMed ID: 24261605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.